Compare Stocks: OCUL, DFTX, INDV, and ARQT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$31.59 +0.4%	$26.42	$19.30 ▼ $33.30	$3.97B	1.57	1.83 million shs	714,501 shs
DFTX Definium Therapeutics	$38.36 +0.7%	$38.11	$10.46 ▼ $49.70	$5.15B	2.19	2.23 million shs	507,782 shs
INDV Indivior	$35.57 +2.3%	$35.32	$27.68 ▼ $42.81	$4.18B	0.87	2.21 million shs	2.03 million shs
OCUL Ocular Therapeutix	$7.47 +2.5%	$8.98	$6.00 ▼ $16.44	$1.64B	1	3.91 million shs	788,443 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-0.73%	-1.32%	+15.08%	+12.36%	+26.05%
DFTX Definium Therapeutics	+2.75%	+7.35%	-0.81%	-14.36%	+196.04%
INDV Indivior	+0.14%	-0.06%	-5.72%	-13.55%	+39.58%
OCUL Ocular Therapeutix	+8.48%	+12.50%	-4.83%	-13.93%	-36.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$31.59 +0.4%	$26.42	$19.30 ▼ $33.30	$3.97B	1.57	1.83 million shs	714,501 shs
DFTX Definium Therapeutics	$38.36 +0.7%	$38.11	$10.46 ▼ $49.70	$5.15B	2.19	2.23 million shs	507,782 shs
INDV Indivior	$35.57 +2.3%	$35.32	$27.68 ▼ $42.81	$4.18B	0.87	2.21 million shs	2.03 million shs
OCUL Ocular Therapeutix	$7.47 +2.5%	$8.98	$6.00 ▼ $16.44	$1.64B	1	3.91 million shs	788,443 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-0.73%	-1.32%	+15.08%	+12.36%	+26.05%
DFTX Definium Therapeutics	+2.75%	+7.35%	-0.81%	-14.36%	+196.04%
INDV Indivior	+0.14%	-0.06%	-5.72%	-13.55%	+39.58%
OCUL Ocular Therapeutix	+8.48%	+12.50%	-4.83%	-13.93%	-36.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.73	Moderate Buy	$38.00	20.83% Upside
DFTX Definium Therapeutics	2.95	Moderate Buy	$66.00	73.23% Upside
INDV Indivior	3.00	Buy	$45.50	30.86% Upside
OCUL Ocular Therapeutix	2.83	Moderate Buy	$22.86	213.54% Upside

Current Analyst Ratings Breakdown

Latest OCUL, DFTX, INDV, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	INDV Indivior	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$43.00 ➝ $45.00
10/20/2026	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/19/2026	ARQT Arcutis Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$38.00 ➝ $44.00
10/19/2026	DFTX Definium Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/19/2026	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$18.00
10/15/2026	DFTX Definium Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	OCUL Ocular Therapeutix	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	ARQT Arcutis Biotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$48.00
10/14/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C) ➝ Hold (C-)
10/11/2026	OCUL Ocular Therapeutix	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$14.00
10/11/2026	OCUL Ocular Therapeutix	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$376.07M	10.51	N/A	N/A	$1.55 per share	20.29
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	$3.36 per share	N/A
INDV Indivior	$1.33B	3.08	$2.74 per share	12.68	($0.78) per share	-44.58
OCUL Ocular Therapeutix	$51.95M	30.82	N/A	N/A	$3.07 per share	2.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	149.77	29.67	N/A	6.15%	15.05%	6.51%	11/4/2026 (Estimated)
DFTX Definium Therapeutics	-$183.79M	-$3.43	N/A	N/A	N/A	N/A	-84.01%	-63.66%	N/A
INDV Indivior	$210M	$2.79	12.46	9.08	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)

Latest OCUL, DFTX, INDV, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	ARQT Arcutis Biotherapeutics	$0.18	N/A	N/A	N/A	$142.59 million	N/A
11/3/2026	Q3 2026	OCUL Ocular Therapeutix	-$0.3635	N/A	N/A	N/A	$14.27 million	N/A
10/29/2026	Q3 2026	INDV Indivior	$1.06	$1.32	+$0.26	$1.12	$329.35 million	$356.00 million
8/6/2026	Q2 2026	DFTX Definium Therapeutics	-$0.55	-$1.44	-$0.89	-$1.44	N/A	N/A
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Latest OCUL, DFTX, INDV, and ARQT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/16/2026	INDV Indivior	special	$8.13			10/30/2026	11/6/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
DFTX Definium Therapeutics	0.04	6.95	6.95
INDV Indivior	N/A	0.84	0.66
OCUL Ocular Therapeutix	0.14	13.10	13.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
DFTX Definium Therapeutics	27.91%
INDV Indivior	60.33%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
DFTX Definium Therapeutics	2.40%
INDV Indivior	0.74%
OCUL Ocular Therapeutix	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	354	125.69 million	113.88 million	Optionable
DFTX Definium Therapeutics	40	134.37 million	131.14 million	Optionable
INDV Indivior	838	118.03 million	117.16 million	Optionable
OCUL Ocular Therapeutix	325	219.62 million	212.81 million	Optionable

OCUL, DFTX, INDV, and ARQT Headlines

Recent News About These Companies

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

October 29 at 7:00 AM | globenewswire.com

Ocular Therapeutix (OCUL) Set to Announce Earnings on Tuesday

October 27 at 7:10 AM | marketbeat.com

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

October 25, 2026 | seekingalpha.com

Transcript : Ocular Therapeutix, Inc. - Special Call

October 23, 2026 | marketscreener.comM

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript

October 23, 2026 | seekingalpha.com

Ocular Therapeutix (NASDAQ:OCUL) Stock Rating Reaffirmed as Buy by Needham & Company LLC

October 21, 2026 | americanbankingnews.com

Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says

October 20, 2026 | finance.yahoo.com

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win

October 20, 2026 | marketbeat.com

Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 10.41%

October 19, 2026 | aaii.comA

Ocular Therapeutix (NASDAQ:OCUL) Given Buy Rating at Needham & Company LLC

October 19, 2026 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Hits New 12-Month Low - Time to Sell?

October 19, 2026 | marketbeat.com

Ocular Therapeutix, Inc. (OCUL) Presents at American Academy of Ophthalmology Retina Subspeciality Day - Slideshow

October 15, 2026 | seekingalpha.com

Ocular Therapeutix (NASDAQ:OCUL) Stock Lifted to "Strong-Buy" by UBS Group

October 14, 2026 | marketbeat.com

Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

October 14, 2026 | theglobeandmail.com

Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 Shares

October 13, 2026 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Has Average Price Target of $24.33 According to Brokerages

October 11, 2026 | marketbeat.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2026 | globenewswire.com

Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Peter Kaiser Sells 9,990 Shares

October 7, 2026 | insidertrades.com

Ocular Therapeutix, Inc. (OCUL) Presents at Euretina 2026 - Slideshow

October 6, 2026 | seekingalpha.com

Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $70,429.50 in Stock

October 6, 2026 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Insider Sells 10,869 Shares of Company Stock

October 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, DFTX, INDV, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$31.59 +0.14 (+0.45%)

As of 12:52 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Definium Therapeutics NASDAQ:DFTX

$38.36 +0.26 (+0.68%)

As of 12:34 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Indivior NASDAQ:INDV

$35.57 +0.80 (+2.30%)

As of 12:53 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Ocular Therapeutix NASDAQ:OCUL

$7.47 +0.18 (+2.47%)

As of 12:53 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCUL, DFTX, INDV, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCUL, DFTX, INDV, and ARQT Earnings

Compare Dividends

Latest OCUL, DFTX, INDV, and ARQT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCUL, DFTX, INDV, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, DFTX, INDV, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Definium Therapeutics NASDAQ:DFTX

Indivior NASDAQ:INDV

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCUL, DFTX, INDV, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCUL, DFTX, INDV, and ARQT Earnings

Compare Dividends

Latest OCUL, DFTX, INDV, and ARQT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCUL, DFTX, INDV, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, DFTX, INDV, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Definium Therapeutics NASDAQ:DFTX

Indivior NASDAQ:INDV

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools